• Pacific Biosciences Releases Epigenetics Software

    Bio-IT World | Pacific Biosciences has released new software for identifying epigenetic modifcations in DNA, which could provide an important advance in studying the chemical modulation of gene activity in health and disease.

    Jun 19, 2012

  • Tending the Body's Microbial Garden

    New York Times | Scientists are making big strides in documenting the medical ecology of the microbiome -- the 100 trillion microbes that make human beings their home.

    Jun 19, 2012

  • NYGC Eyes Permanent Home in Manhattan

    Wall Street Journal | The New York Genome Center is in the final stages of negotiating a deal for about 150,000 square feet at 101 Sixth Ave., in the SoHo neighborhood of Manhattan, signaling the home stretch for the center's six-month search for a permanent home.

    Jun 18, 2012

  • Ambry Genetics Catches the Clinical Sequencing Wave

    Bio-IT World | After launching its CLIA Exome sequencing service six months ago, Ambry Genetics has quietly dropped the price to $7,900 for a trio. But potentially cannabilizing a thriving molecular diagnostics business is far from the only thing that makes Ambry stand out.  

    Jun 12, 2012

  • Finish What We Started: Dietrich Stephan’s Silicon Valley Biosystems Opens Genome Interpretation Floodgates

    Bio-IT World | In an exclusive briefing with Bio-IT World, the co-founder of Navigenics, Dietrich Stephan, says he aims to “finish what we started” with the commercial launch of a new genome interpretation company, Silicon Valley Biosystems (SVBio). 

    Jun 12, 2012

  • June Free Trials and Downloads

    Bio-IT World | Free trials and downloads for June.

    Jun 11, 2012

  • Foundation Medicine, Novartis Partner for Clinical Trial Enrollment

    Foundation Medicine | Foundation Medicine and Novartis are partnering on cancer drug testing. Novartis plans to use Foundation's technology as part of its cancer trial enrollment process over the next three years, focusing on Phase 1 and 2 oncology clinical programs. 

    Jun 10, 2012

  • FDA Delays Decision on HIV Pill

    San Francisco Chronicle | FDA has announced a delay in its decision on Gilead Sciences' HIV-prevention pill, choosing to take another three months to review the application and supporting materials.

    Jun 10, 2012

  • Genentech Gets FDA Approval for Combo Treatment

    Xconomy | Genentech announced early results of a new drug targeting HER2-expressing cancers early last week, and later received FDA approval to market Perjeta in combination with Herceptin and Taxotere. 

    Jun 10, 2012

  • Fetal Sequencing Based on Mother's Blood, Father's Saliva

    New York Times | Researchers are now able to determine a fetus's entire genome from the mother's blood and the father's saliva. 

    Jun 7, 2012

  • David Ho Highlights Launch of Bio-IT Asia Conference

    Bio-IT World | SINGAPORE—Ten years after the launch of the Bio-IT World Conference & Expo series in Boston, the conference made its debut in Asia in the sparkling Marina Bay Sands convention center. The trio of speakers who opened the three-day meeting was veteran HIV researcher David Ho, bio-IT consultant Chris Dagdigian, and AstraZeneca bioinformatician Yaron Turpaz. 

    Jun 6, 2012

  • Does Thimerosal Prevent Autism? Epidemiology Gone Wild

    Bio-IT World | The Skeptical Outsider | Human beings are born pattern recognizers, part of the repertoire of survival skills that separates us from the beasts. We are programmed to spot relationships that we are looking for, sometimes when they're not even there. This occasionally causes us to leap to questionable conclusions that can wreak all sorts of havoc. 

    Jun 6, 2012

  • Quake Wins $500K Lemelson-MIT Prize

    Mass High Tech | Stephen Quake, Helicos co-founder and Stanford University professor, has been recognized as this year's Lemelson-MIT Prize winner. He is being recognized for his invention of an improved method for measuring the immune system along with other work. 

    Jun 6, 2012

  • Complete Genomics Cuts Jobs, Starts Review

    Bloomberg Businessweek | Complete Genomics is laying off about 20 percent of its workforce and has hired a financial adviser, Jeffries & Co., to help it explore various strategic options including a possible merger or sale of the company.

    Jun 6, 2012

  • What's In a Name?

    Xconomy | Biotech companies change their names for many reasons, some good, some questionable. Xconomy looks at the old and new names of several biotechs. 

    Jun 4, 2012

  • Best Practices: Safety Rules for ELNs

    Bio-IT World Best Practices | Keeping track of all of the safety rules for reactions and reagents was an overwhelming proposal, so the chemistry safety officers at Bristol-Myers Squibb recruited informatics help to see if there was another option. The resulting electronic laboratory notebook customization earned a best practices nod by the judges in the 2012 Bio-IT World Best Practices Awards competition. 

    Jun 4, 2012

  • Investing in the Abandoned

    Forbes | When it comes to investing, pharma might point the way to areas of high return--if you take a look at what the sector is abandoning. 

    Jun 3, 2012

  • Genomics-Enabled Prevention

    Forbes | Ronald Davis, director of the Stanford Genome Technology Center, believes the time to invest in genomics and personalized medicine is now. 

    Jun 3, 2012

  • Genentech's New and Improved Herceptin

    Xconomy | Genentech and ImmunoGen have released early results of an experimental drug, trastuzumab emtansine (T-DM1), that targets HER2-expressing breast cancers. The drug combines the targeting capabilities of Genetech's Herceptin with an additional tumor toxin thanks to a chemical linker from ImmunoGen. 

    Jun 3, 2012

  • Bio-IT World News Briefs: May

    Bio-IT World | News briefs and bits from the biotech industry in May.

    Jun 1, 2012